dc.contributor.author
Torres-Arzayus, Maria I.
dc.contributor.author
Font de Mora, Jaime
dc.contributor.author
Yuan, Jing
dc.contributor.author
Vazquez, Francisca
dc.contributor.author
Bronson, Roderick
dc.contributor.author
Rué i Monné, Montserrat
dc.contributor.author
Sellers, William R.
dc.contributor.author
Brown, Myles
dc.date.accessioned
2024-12-05T21:30:57Z
dc.date.available
2024-12-05T21:30:57Z
dc.date.issued
2016-05-19T08:53:52Z
dc.date.issued
2025-01-01
dc.identifier
https://doi.org/10.1016/j.ccr.2004.06.027
dc.identifier
http://hdl.handle.net/10459.1/57053
dc.identifier.uri
http://hdl.handle.net/10459.1/57053
dc.description.abstract
The gene encoding AIB1, an estrogen receptor coactivator, is amplified in a subset of human breast cancers. Here we
show that overexpression of AIB1 in transgenic mice (AIB1-tg) leads to mammary hypertrophy, hyperplasia, abnormal
postweaning involution, and the development of malignant mammary tumors. Tumors are also increased in other organs,
including the pituitary and uterus. AIB1 overexpression increases mammary IGF-I mRNA and serum IGF-I protein levels.
In addition, IGF-I receptor and downstream signaling molecules are activated in primary mammary epithelial cells and
mammary tumor cells derived from AIB1-tg mice. Knockdown of AIB1 expression in cultured AIB1-tg mammary tumor
cells leads to reduced IGF-I mRNA levels and increased apoptosis, suggesting that an autocrine IGF-I loop underlies the
mechanism of AIB1-induced oncogenesis.
dc.relation
Reproducció del document publicat a https://doi.org/10.1016/j.ccr.2004.06.027
dc.relation
Cancer Cell, 2004, vol. 6, núm. 3, p. 263-274
dc.rights
(c) Cell Press, 2004
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.title
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene